|
|
 | | | |
- close
- close
- close
- close
Optimer Pharmaceuticals (OPTR) |
Suggest other news sources for this topic
WIKI ANALYSIS
Optimer Pharmaceuticals Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The company is currently focused on the development of products that treat gastrointestinal (GI) infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. Optimer has two late-stage anti-infective product candidates, Difimicin and Prulifloxacin. Difimicin (OPT-80) is an antibiotic currently in a phase III registration trial for the treatment of Clostridium difficile-associated diarrhea (CDAD), the most common nosocomial, or hospital-acquired, diarrhea. Prulifloxacin is an antibiotic currently in two phase III trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Optimer is also developing additional product candidates using its proprietary technology, including Optimer One-Pot Synthesis (OPopS) drug discovery platform. The following table summarizes the major clinical/preclinical drug candidates:
Product Candidate
Target Indications
Development Status
Commercial Rights
Anti-Infectives
Difimicin (OPT-80)
CDAD treatment
Phase III
Optimer worldwide
CDAD prevention
Proof-of-concept Trial
Prevention of VRE bloodstream infections
Proof-of-concept Trial
MRS prophylaxis
Nasal carriage
Formulation
Catheter-related
Formulation
Prulifloxacin (OPT-99)
Infectious diarrhea
Phase III
Optimer U.S.
OPT-1068/OPT-1273
Respiratory tract infections
Pre-clinical
Cempra worldwide
Other Therapeutics
OPT-822/OPT-821
Breast cancer
Planning Phase II
Optimer worldwide
OPT-88
Osteoarthritis
Pre-clinical
Optimer worldwide
In February, 2007, Optimer went public by issuing 7 million shares of common stock at a price of $7.00 per share, resulting in aggregate proceeds of approximately $43.6 million, net of underwriting discounts and commissions and offering expenses. In addition, in February 2007, the underwriters exercised in full the over-allotment option to purchase an additional 1.1 million shares of the company's common stock from a selling stockholder.
Optimer was incorporated in Delaware in November, 1998 and is headquartered in San Diego, California. Optimer has a wholly owned subsidiary, Optimer Biotechnology, Inc., in Taiwan.
References
| |||||||
